

## *Division of Signal Transduction Therapy*

### **Standard Operating Procedure**

#### **Preparation of DAZAP T86A [2 - 407]**

**Enzyme description:-** DAZAP T86A [2 - 407]

**Clone number:-** DU 3216

**Source:-** Recombinant

**Expression system:-** *E.coli*

**Tag:-** N-terminal GST

**Purification method:-** GSH Sepharose

**Calculated molecular mass:-**

Monoisotopic 70,001.64 daltons

Average Mass 70,046.34 daltons

[cysteines reduced, methionines have not been oxidised]

**Theoretical pI:-** 6.87

**Purity:-** >80 %

**Enzyme storage buffer:-**

50 mM Tris-HCl pH 7.5, 270 mM Sucrose, 150 mM NaCl, 0.1 mM EGTA,  
0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF

**Storage temperature:-** -70 °C

## *Division of Signal Transduction Therapy*

### Clone Data Sheet

#### DAZAP T86A [2 - 407]

<b><u>Protein</u></b>	DAZAP T86A [2 - 407]
<b><u>Clone number</u></b>	DU 3216
<b><u>Species</u></b>	Human
<b><u>Accession number</u></b>	NM_018959.3
<b><u>Tags</u></b>	N-terminal GST
<b><u>Bacterially expressed protein</u></b>	<p>MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELG LEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAIEISMLEGA VLDIRYGVSR IAYS KDFETLKVDFLSKLP EMLKMFEDRLCHKTYLNGDH VTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPOIDKYLKSS KYIAWPLQGWQATFGGGDHPPKSDLEVL FQGPLGSNNSGADEIGKLFVG <b>GLDWSTTQETLRSYFSQYGEVVDCVIMKDKT TNQSRGFGFVKFKDPNCV</b> <b>GTVLASRPHTLDGRNIDPKPCA PRGMQPERTRPKEGWQKGPRSDNSKSN</b> <b>KIFVGGI PHNCGETELREYFKKF GVVTEVVM IYDAEKQRPRGFGF ITFE</b> <b>DEQSV DQAVNMHFHDIMGKKVEVKRAEPRDSKSQAPGQPGASQWGSRVV</b> <b>PNAANGWAGQPPPTWQQGYGPOGMWVPAGQAIGGYGPPPPAGRGAPPPP</b> <b>PFTSYIVSTPPGGFPPPQGFPOGYGAPPQFSFGYGPPPPPPDQFAPPGV</b> <b>PPPPATPGAAPLAFPPPPSQAAPDMSKPPTAQPDPYPYGQYAGYGQDLSG</b> <b>FGQGFSDPSQPPPSYGGPSVPGSGGPPAGGSGFGRGQNHNVQGFHPYRR</b></p>
<b><u>Native sequence</u></b>	<p>Amino acids N2 – R407 (end) of human DAZAP. Residue N232 of the fusion protein is equivalent to N2 of the native enzyme. The GST tag is located at residues 1 – 220. The protein has a T86A mutation. Residue T269 is equivalent to residue A316 of the fusion protein.</p>
<b><u>Protease cleavage</u></b>	PreScission (LEVL FQGP) residues 221 - 228
<b><u>Cloning sites</u></b>	<i>Bam</i> H1 sites of pGEX6P-1

## *Division of Signal Transduction Therapy*

### **Nucleotide** **Sequence of insert**

ggatccAACAACTCGGGCGCCGACGAGATCGGGAAGCTCTTCGTGGGCGGTCTTGACTG  
GAGCACGACCCAAGAGACTCTGCGCAGCTACTTTTCCCAATATGGAGAAGTCGTAGATT  
GTGTTATCATGAAAAGATAAAAACCACCAACCAGTCTCGAGGCTTTGGGTTTGTCAAATTT  
AAAGACCCAAACTGTGTGGGGACGGTGCTGGCCAGCAGACCGCACACGCTAGATGGCCG  
AAACATCGACCCAAGCCATGCGCACCCCGGGGATGCAGCCGGAGAGAACACGGCCGA  
AGGAAGGATGGCAGAAAGGACCCAGGAGCGATAACAGTAAATCAAATAAGATATTTGTC  
GGTGAATTCCCTACAATTGTGGTGAGACAGAGCTCAGGGAATACTTCAAGAAGTTCGG  
AGTGGTCACGGAGGTAGTCATGATCTATGACGCCGAGAAGCAGAGGCCCGGAGGTTTTG  
GATTTATTACTTTTCGAGGACGAACAATCAGTGGACCAGGCTGTCAACATGCATTTTCAC  
GACATCATGGGCAAAAAAGTGAAGTTAAACGAGCTGAGCCTCGGGACAGCAAGAGCCA  
AGCGCCGGGACAGCCAGGTGCCAGCCAGTGGGGGAGCCGGGTTGTGCCCAACGCTGCCA  
ATGGCTGGGCAGGCCAGCCCCCGCCACGTGGCAGCAAGGATATGGCCCGCAAGGAATG  
TGGGTGCCGGCAGGACAGGCGATTGGTGGCTATGGACCGCCCCCTGCAGGAAGAGGAGC  
CCCCCGCCACCCACCCTTACCTCCTACATCGTGTCCACCCCTCCTGGAGGCTTTC  
CCCCCCCCAGGGCTTCCCTCAGGGCTACGGTGCCCCGCCACAGTTCAGTTTTGGCTAC  
GGCCTCCACCTCCACCGCCAGATCAGTTTGCCCCCTCCGGGGGTTCCCTCCTCCACCAGC  
CACTCCCGGGCAGCACCTCTGGCTTTCCCACCGCCTCCGTCTCAGGCTGCCCGGACA  
TGAGCAAGCCCCGACAGCTCAGCCAGACTTCCCCTATGGTCAGTATGCAGGTTACGGG  
CAGGACTTGAGTGGCTTCGGACAGGGCTTCTCAGACCCAGCCAGCAGCCTCCTTCCTA  
CGGGGTCCCTCCGTGCCAGGGTCGGGGGGCCCCCGCCGGCGGCAGCGGCTTTGGAC  
GAGGGCAGAACCACAACGTGCAAGGGTTCACCCCTACCGACGctaggatcc